Impact of the COVID-19 pandemic on antipsychotic prescribing in individuals with autism, dementia, learning disability, serious mental illness or living in a care home: a federated analysis of 59 million patients' primary care records in situ using OpenSAFELY.

Autor:	Macdonald O; Pharmacy, Oxford Health NHS Foundation Trust, Oxford, UK orla.macdonald@oxfordhealth.nhs.uk., Green A; Nuffield Department of Primary Care, Oxford University, Oxford, UK., Walker A; Nuffield Department of Primary Care, Oxford University, Oxford, UK., Curtis H; Nuffield Department of Primary Care, Oxford University, Oxford, UK., Croker R; Nuffield Department of Primary Care, Oxford University, Oxford, UK., Brown A; Nuffield Department of Primary Care, Oxford University, Oxford, UK., Butler-Cole B; Nuffield Department of Primary Care, Oxford University, Oxford, UK., Andrews C; Nuffield Department of Primary Care, Oxford University, Oxford, UK., Massey J; Nuffield Department of Primary Care, Oxford University, Oxford, UK., Inglesby P; Nuffield Department of Primary Care, Oxford University, Oxford, UK., Morton C; Nuffield Department of Primary Care, Oxford University, Oxford, UK., Fisher L; Nuffield Department of Primary Care, Oxford University, Oxford, UK., Morley J; Nuffield Department of Primary Care, Oxford University, Oxford, UK., Mehrkar A; Nuffield Department of Primary Care, Oxford University, Oxford, UK., Bacon S; Nuffield Department of Primary Care, Oxford University, Oxford, UK., Davy S; Nuffield Department of Primary Care, Oxford University, Oxford, UK., Evans D; Nuffield Department of Primary Care, Oxford University, Oxford, UK., Dillingham I; Nuffield Department of Primary Care, Oxford University, Oxford, UK., Ward T; Nuffield Department of Primary Care, Oxford University, Oxford, UK., Hulme W; Nuffield Department of Primary Care, Oxford University, Oxford, UK., Bates C; TPP-UK, Leeds, UK., Cockburn J; TPP-UK, Leeds, UK., Parry J; TPP-UK, Leeds, UK., Hester F; TPP-UK, Leeds, UK., Harper S; TPP-UK, Leeds, UK., O'Hanlon S; EMIS Group PLC, Leeds, UK., Eavis A; EMIS Group PLC, Leeds, UK., Jarvis R; EMIS Group PLC, Leeds, UK., Avramov D; EMIS Group PLC, Leeds, UK., Parkes N; EMIS Group PLC, Leeds, UK., Wood I; EMIS Group PLC, Leeds, UK., Goldacre B; Nuffield Department of Primary Care, Oxford University, Oxford, UK., Mackenna B; Nuffield Department of Primary Care, Oxford University, Oxford, UK.
Jazyk:	angličtina
Zdroj:	BMJ mental health [BMJ Ment Health] 2023 Sep; Vol. 26 (1).
DOI:	10.1136/bmjment-2023-300775
Abstrakt:	Background: The COVID-19 pandemic affected how care was delivered to vulnerable patients, such as those with dementia or learning disability. Objective: To explore whether this affected antipsychotic prescribing in at-risk populations. Methods: With the approval of NHS England, we completed a retrospective cohort study, using the OpenSAFELY platform to explore primary care data of 59 million patients. We identified patients in five at-risk groups: autism, dementia, learning disability, serious mental illness and care home residents. We calculated the monthly prevalence of antipsychotic prescribing in these groups, as well as the incidence of new prescriptions in each month. Findings: The average monthly rate of antipsychotic prescribing increased in dementia from 82.75 patients prescribed an antipsychotic per 1000 patients (95% CI 82.30 to 83.19) in January-March 2019 to 90.1 (95% CI 89.68 to 90.60) in October-December 2021 and from 154.61 (95% CI 153.79 to 155.43) to 166.95 (95% CI 166.23 to 167.67) in care homes. There were notable spikes in the rate of new prescriptions issued to patients with dementia and in care homes. In learning disability and autism groups, the rate of prescribing per 1000 decreased from 122.97 (95% CI 122.29 to 123.66) to 119.29 (95% CI 118.68 to 119.91) and from 54.91 (95% CI 54.52 to 55.29) to 51.04 (95% CI 50.74 to 51.35), respectively. Conclusion and Implications: We observed a spike in antipsychotic prescribing in the dementia and care home groups, which correlated with lockdowns and was likely due to prescribing of antipsychotics for palliative care. We observed gradual increases in antipsychotic use in dementia and care home patients and decreases in their use in patients with learning disability or autism. Competing Interests: Competing interests: No, there are no competing interests. (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu